Search company, investor...
Silverback Therapeutics company logo

Silverback Therapeutics

silverbacktx.com

Founded Year

2016

Stage

IPO | IPO

Total Raised

$211M

Date of IPO

12/4/2020

Market Cap

0.22B

Stock Price

6.18

About Silverback Therapeutics

Silverback Therapeutics (Nasdaq: SBTX) is a biotechnology company that develops a pipeline of systemically delivered, locally active therapies that can be administered to patients. The active therapies only act at the sites of disease, sparing healthy tissues from unwanted side effects.

Headquarters Location

500 Fairview Ave N Suite 600

Seattle, Washington, 98109,

United States

206-456-2900

Missing: Silverback Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Silverback Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Silverback Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Silverback Therapeutics in 1 CB Insights research brief, most recently on Mar 24, 2020.

Expert Collections containing Silverback Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Silverback Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Silverback Therapeutics Patents

Silverback Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Immunology
  • Radiation therapy
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/19/2021

11/23/2021

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs

Grant

Application Date

2/19/2021

Grant Date

11/23/2021

Title

Related Topics

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs

Status

Grant

Latest Silverback Therapeutics News

ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger

Nov 22, 2022

Author(s): Fintel StaffFintel reports that Lowenthal Richard E has filed a 13D form with the SEC disclosing ownership of 7,422,432 shares of Silverback Therapeutics Inc (SBTX). This represents 7.9% of the company. On Nov. 8, ARS closed its merger with Silverback. The combined company operates as ARS Pharmaceuticals, Inc. Silverback Therapeutics, Inc. operates as a biotechnology company. The […]

Silverback Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Silverback Therapeutics Rank

Silverback Therapeutics Frequently Asked Questions (FAQ)

  • When was Silverback Therapeutics founded?

    Silverback Therapeutics was founded in 2016.

  • Where is Silverback Therapeutics's headquarters?

    Silverback Therapeutics's headquarters is located at 500 Fairview Ave N, Seattle.

  • What is Silverback Therapeutics's latest funding round?

    Silverback Therapeutics's latest funding round is IPO.

  • How much did Silverback Therapeutics raise?

    Silverback Therapeutics raised a total of $211M.

  • Who are the investors of Silverback Therapeutics?

    Investors of Silverback Therapeutics include OrbiMed Advisors, Pontifax, Nextech Invest, U.S. Venture Partners, Nantahala Capital Management and 13 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.